Read on Twitter
#EVG
Recently bought Evgen Pharma
Small initial stake as I believe a placing maybe near
If correct I will top up Post placing
P2/3 trial in ARDS Feat COVID19 Patients targeting the Nrf2 pathway to reduce lung inflammation
Could have a v big year if proven effective
Recently bought Evgen Pharma
Small initial stake as I believe a placing maybe near
If correct I will top up Post placing
P2/3 trial in ARDS Feat COVID19 Patients targeting the Nrf2 pathway to reduce lung inflammation
Could have a v big year if proven effective
#EVG
Significantly oversubscribed placing raising a vast amount compared to MCap
Truly shows its potential and just how undervalued it is at this price
Evgen Pharma PLC - Placing and Open Offer to raise up to £11 million #EVG https://www.voxmarkets.co.uk/rns/announcement/6af890e0-dc5c-4404-91bd-a082d94d31af #voxmarkets
Significantly oversubscribed placing raising a vast amount compared to MCap
Truly shows its potential and just how undervalued it is at this price
Evgen Pharma PLC - Placing and Open Offer to raise up to £11 million #EVG https://www.voxmarkets.co.uk/rns/announcement/6af890e0-dc5c-4404-91bd-a082d94d31af #voxmarkets
#EVG
Could Evgen Pharma become the next #SNG?
Both developing a late stage Therapeutic targeting COVID19
MCaps
#EVG £14m
#SNG £353m
(25 TIMES higher than Evgen)
Could Evgen Pharma become the next #SNG?
Both developing a late stage Therapeutic targeting COVID19
MCaps
#EVG £14m
#SNG £353m
(25 TIMES higher than Evgen)
#EVG 
Evgen is a company that have created a synthetic drug based on sulforaphane using their Sulforadex® technology
Sulforaphane is a very unstable molecule found in
SUPER FOODS at very low concentrations which have remarkable health benefits
Evgen is a company that have created a synthetic drug based on sulforaphane using their Sulforadex® technology
Sulforaphane is a very unstable molecule found in
SUPER FOODS at very low concentrations which have remarkable health benefits
#EVG
Evgen's lead product SFX-01, is a patent-protected complex of sulforaphane and alpha-cyclodextrin in a stable powder which can be encapsulated inside a pill and easy to administer
Evgen's lead product SFX-01, is a patent-protected complex of sulforaphane and alpha-cyclodextrin in a stable powder which can be encapsulated inside a pill and easy to administer
#EVG
Combining Sulforaphane with Alpha-cyclodextrin allows the body to absorb the potent anti oxidant to a much higher degree increasing its anti-cancer and anti inflammatory effects on the body
Combining Sulforaphane with Alpha-cyclodextrin allows the body to absorb the potent anti oxidant to a much higher degree increasing its anti-cancer and anti inflammatory effects on the body
#EVG
SFX-01 is currently being studies in 3 areas
-Cancers including Brain and Breast
-Lung Inflammation ARDS including COVID19
-Longevity (Living Longer) partnered with Juvenesence (Specialist Longevity company valued at $500m in 2019)
SFX-01 is currently being studies in 3 areas
-Cancers including Brain and Breast
-Lung Inflammation ARDS including COVID19
-Longevity (Living Longer) partnered with Juvenesence (Specialist Longevity company valued at $500m in 2019)
#EVG
SFX-01 lead indication is in ARDS including COVID19
This is potentially a game changer for EVG
Their Phase 2/3 trial rapidly recruiting with potential for Market authorisation this year
ARDS is wide spread lung inflammation
SFX-01 lead indication is in ARDS including COVID19
This is potentially a game changer for EVG
Their Phase 2/3 trial rapidly recruiting with potential for Market authorisation this year
ARDS is wide spread lung inflammation
#EVG
Disregarding COVID19
2.2million people Globally suffer and are diagnosed with ARDS every year
including
150,000 to 200,000 Americans
Disregarding COVID19
2.2million people Globally suffer and are diagnosed with ARDS every year
including
150,000 to 200,000 Americans
#EVG
We have been able to significantly reduce the rate of death due to ARDS from 70% to 35% due to physical practices
However, there still remains A LARGE UNMET NEED
35% of people with ARDS (770,000 people) die every year on average with the primary cause diagnosed as ARDS
We have been able to significantly reduce the rate of death due to ARDS from 70% to 35% due to physical practices
However, there still remains A LARGE UNMET NEED
35% of people with ARDS (770,000 people) die every year on average with the primary cause diagnosed as ARDS
#EVG
Evgen's SFX-01 is a
highly potent synthetically engineered Sulforaphane molecule which importantly regulates the
Nrf2 pathway
The Nrf2 pathway regulates over 200 genes CONTROLLING a staggering 3-5% of our cells
Evgen's SFX-01 is a
highly potent synthetically engineered Sulforaphane molecule which importantly regulates the
Nrf2 pathway
The Nrf2 pathway regulates over 200 genes CONTROLLING a staggering 3-5% of our cells
#EVG
Nrf2 pathway
-Reduce inflammation
-Powerfully protects maintains and restores healthy function in the cell
Nrf2 pathway
-Reduce inflammation
-Powerfully protects maintains and restores healthy function in the cell
#EVG
The effects described above have a RAPID onset, reducing inflammation and restoring normal cell function within 30 minutes IN THE LUNGS
Could this be the Key to reducing death by ARDS?
The effects described above have a RAPID onset, reducing inflammation and restoring normal cell function within 30 minutes IN THE LUNGS
Could this be the Key to reducing death by ARDS?
#EVG
ARDS is one of the biggest problematic conditions within the COVID19 illness as this study clearly points out
75% of COVID Patients transferred to ICU is due to ARDS
90% of ALL COVID patients have ARDS as a contributing factor
45% ARDS is primary factor of death
ARDS is one of the biggest problematic conditions within the COVID19 illness as this study clearly points out
75% of COVID Patients transferred to ICU is due to ARDS90% of ALL COVID patients have ARDS as a contributing factor45% ARDS is primary factor of death
#EVG
Further evidence of the thesis that Nrf2 plays a key role in preventing deterioration of ARDS in COVID patients
IL6 cytokine (the main damaging chemical causing cytokine storm inflammation) can be supressed by activation of the Nrf2 pathway
7min
Further evidence of the thesis that Nrf2 plays a key role in preventing deterioration of ARDS in COVID patients
IL6 cytokine (the main damaging chemical causing cytokine storm inflammation) can be supressed by activation of the Nrf2 pathway
7min
#EVG
I hope I am allowing you to build up a picture as to why Life Arc
(a specialist medical innovation charity accelerating promising therapies to patients treatment protocols) specifically selected SFX-01 for trials in ARDS featuring COVID https://www.lifearc.org/funding/covid-19-funding-2/sfx-01/
I hope I am allowing you to build up a picture as to why Life Arc
(a specialist medical innovation charity accelerating promising therapies to patients treatment protocols) specifically selected SFX-01 for trials in ARDS featuring COVID https://www.lifearc.org/funding/covid-19-funding-2/sfx-01/
#EVG
Life Arc received over 130 applications for grant funding for their COVID Initiative to find breakthrough therapies
SFX-01 was classed as one of the most promising therapies and was selected with only 12 other therapies
Life Arc received over 130 applications for grant funding for their COVID Initiative to find breakthrough therapies
SFX-01 was classed as one of the most promising therapies and was selected with only 12 other therapies
#EVG
Life Arc has played key roles in therapies being approved INCLUDING ground breaking drugs such as KEYTRUDA and Tocilizumab
Life Arc has played key roles in therapies being approved INCLUDING ground breaking drugs such as KEYTRUDA and Tocilizumab
#EVG
The board at Life Arc are very experienced with their CEO having decades of the experience in Research and Development at major Pharmaceutical giants all around the world
Currently sitting on the board of directors at Sanofi valued
98BILLION
The board at Life Arc are very experienced with their CEO having decades of the experience in Research and Development at major Pharmaceutical giants all around the world
Currently sitting on the board of directors at Sanofi valued
98BILLION
#EVG
A key note
Tocilimab ALSO an IL6 inhibitor has been approved for use in COVID19 based on a Phase 3 data, with 353 patients receiving Tocizilumab
Only reducing the chances of death by a margin of 8.5% (24% from basline of standard of care) https://www.standard.co.uk/news/uk/tocilizumab-sarilumab-covid-drugs-treatment-b743038.html
A key note
Tocilimab ALSO an IL6 inhibitor has been approved for use in COVID19 based on a Phase 3 data, with 353 patients receiving Tocizilumab
Only reducing the chances of death by a margin of 8.5% (24% from basline of standard of care) https://www.standard.co.uk/news/uk/tocilizumab-sarilumab-covid-drugs-treatment-b743038.html
#EVG
This data suggests there is a still a need for further safe and potentially potent anti inflammatory drugs like SFX-01
SFX-01 ARDS inc COVID 'STAR' trial commenced on 23rd November to recruit 300 Patients
https://www.investegate.co.uk/evgen-pharma-plc--evg-/rns/recruitment-of-first-patient-in-star-trial/202011230700060759G/
This data suggests there is a still a need for further safe and potentially potent anti inflammatory drugs like SFX-01
SFX-01 ARDS inc COVID 'STAR' trial commenced on 23rd November to recruit 300 Patients
https://www.investegate.co.uk/evgen-pharma-plc--evg-/rns/recruitment-of-first-patient-in-star-trial/202011230700060759G/
#EVG
At 100 patient mark the trial will retrieve preliminary data on safety + essentially if the drugs shows signs of working
23rdNov- Trial Start
19thJan- 56 Patients (0.96 Patients Per Day)
1st Feb- 89 Patents (2.53 Patients Per Day)
100 Patient Threshold expected 7thFeb
At 100 patient mark the trial will retrieve preliminary data on safety + essentially if the drugs shows signs of working
23rdNov- Trial Start
19thJan- 56 Patients (0.96 Patients Per Day)
1st Feb- 89 Patents (2.53 Patients Per Day)
100 Patient Threshold expected 7thFeb
#EVG
Today the company announced a
SUBSTANTIALLY OVERSUBSCRIBED PLACING
with
HUGE FUNDING in comparison to MCap
This IMO strikes all the hallmarks of a potential #SNG style rerate if preliminary data is positive
Today the company announced a
SUBSTANTIALLY OVERSUBSCRIBED PLACING
with
HUGE FUNDING in comparison to MCap
This IMO strikes all the hallmarks of a potential #SNG style rerate if preliminary data is positive
#EVG
Funding through to 2023... the company may never need to raise again
IND for US trial and ultimately US/FDA approval
'STAR' trial already in progress for approval across UK
and EU
Funding through to 2023... the company may never need to raise again
IND for US trial and ultimately US/FDA approval
'STAR' trial already in progress for approval across UK
and EU
#EVG
It appears by the data provided admission into the trial has accelerated
1. Due to the spike in cases
2. Potentially due to being a priority therapeutic candidate for this illness boding well that medical staff are increasing adoption in the trial https://twitter.com/AimHardy/status/1356739423661137925?s=20
It appears by the data provided admission into the trial has accelerated
1. Due to the spike in cases
2. Potentially due to being a priority therapeutic candidate for this illness boding well that medical staff are increasing adoption in the trial https://twitter.com/AimHardy/status/1356739423661137925?s=20
#EVG
A very important article highlighting and summarising some key hypothesis’ and drivers for COVID viral drift which may potentially make the vaccine ineffective https://www.vox.com/science-and-health/22247525/covid-19-variants-uk-south-africa-brazil-b117-why-now
A very important article highlighting and summarising some key hypothesis’ and drivers for COVID viral drift which may potentially make the vaccine ineffective https://www.vox.com/science-and-health/22247525/covid-19-variants-uk-south-africa-brazil-b117-why-now
#EVG
I believe very much in what the experts are saying that we will always live with the virus due to the fact it mutates more aggressively in presence of Antibodies and especially in immunocompromised/“old” people, as the vaccine rolls out this is key to watch
I believe very much in what the experts are saying that we will always live with the virus due to the fact it mutates more aggressively in presence of Antibodies and especially in immunocompromised/“old” people, as the vaccine rolls out this is key to watch
